Literature DB >> 18195094

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.

Sai Li1, Robert Kralovics, Gennaro De Libero, Alexandre Theocharides, Heinz Gisslinger, Radek C Skoda.   

Abstract

We studied the lineage distribution of JAK2 mutations in peripheral blood of 8 polycythemia vera (PV) patients with exon 12 mutations and in 21 PV patients with JAK2-V617F. Using a quantitative allele discrimination assay, we detected exon 12 mutations in purified granulocytes, monocytes, and platelets of 8 patients studied, but lymphoid cells showed variable involvement and the mutation was absent in T cells. Endogenous erythroid colonies grew in all patients analyzed. One patient displayed erythroid colonies homozygous for the exon 12 mutation with evidence for mitotic recombination on chromosome 9p. In some patients with exon 12 mutations or JAK2-V617F, a proportion of endogenous erythroid colonies were negative for both JAK2 mutations. One patient carried 2 independent clones: one with an exon 12 mutation and a second with JAK2-V617F. The finding of clonal heterogeneity is compatible with the hypothesis that additional clonal events are involved in the pathogenesis of PV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195094     DOI: 10.1182/blood-2007-09-111971

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

Review 3.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

4.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

5.  Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

Authors:  Serge Carillo; Laurent Henry; Eric Lippert; François Girodon; Isabelle Guiraud; Céline Richard; Frédérique Dubois Galopin; Cedric Cleyrat; Eric Jourdan; Robert Kralovics; Sylvie Hermouet; Thierry Lavabre-Bertrand
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

6.  Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

Authors:  Todd S Laughlin; Alison R Moliterno; Brady L Stein; Paul G Rothberg
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

7.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

8.  Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.

Authors:  Yu-Cheng Chang; Huan-Chau Lin; Yi-Hao Chiang; Caleb Gon-Shen Chen; Ling Huang; Wei-Ting Wang; Chun-Chia Cheng; Johnson Lin; Yi-Fang Chang; Ming-Chih Chang; Ruey-Kuen Hsieh; Shu-Jen Chen; Ken-Hong Lim; Yuan-Yeh Kuo
Journal:  Med Oncol       Date:  2017-04-07       Impact factor: 3.064

9.  Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Authors:  Valerie Ugo; Sylvie Tondeur; Marie-Laurence Menot; Nadine Bonnin; Gerald Le Gac; Carole Tonetti; Veronique Mansat-De Mas; Lydie Lecucq; Jean-Jacques Kiladjian; Christine Chomienne; Christine Dosquet; Nathalie Parquet; Luc Darnige; Marc Porneuf; Martine Escoffre-Barbe; Stephane Giraudier; Eric Delabesse; Bruno Cassinat
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

10.  Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Thomas Geer; Peter Müller; Johann Mittermüller; Petro Petrides; Rudolf Schlag; Reiner Sandner; Johannes Selbach; Hans Rainer Slawik; Hans Werner Tessen; Jürgen Wehmeyer; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.